Malaria Clinical Trial
Official title:
Malaria Survey in the Tak Province Refugee Camps
| Verified date | April 2016 |
| Source | University of Oxford |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United Kingdom: Research Ethics Committee |
| Study type | Interventional |
According to the World Malaria Report, there were significant decreases in the number of
P.falciparum (PF) malaria cases worldwide in the past decade. On the Thai-Myanmar border
where transmission is low and seasonal and where incidence of Multi-drugs resistant
P.falciparum parasites is the highest, the same trend has been observed with a clear decline
in malaria episodes and the ratio of P. falciparum/P. vivax (PF/PV.
Economic development, unprecedented financial support, renewed efforts in vector control, a
wider use of rapid diagnosic tests (RDTs) for malaria and the deployment of artemisinin
based combination treatments (ACT) are the main contributing factors to those successes
against malaria.
However the emergence in Cambodia and on the Thai-Myanmar border of P.falciparum isolates
that exhibit resistance to artesunate is threatening those gains . This is characterized by
a slow parasite clearance rate observed in patients treated with artesunate.
At the same time, recent SMRU surveys along the Thai-Burmese border using a new cutting-edge
technology i.e. highly sensitive quantitative Real Time PCR (RT-PCR) able to detect very low
parasitaemia (10 parasites per ml), found up to a 3-5 fold increase in the prevalence of
malaria compared to what is found with the usual diagnostic tools such as microscopy, RDT or
even conventional PCR.
It seems that a large number of asymptomatic carriers with very low parasites counts (a
large potential malaria reservoir) go undetected. If confirmed, this might pose the greatest
obstacle for malaria elimination in the region and containment of artemisinin resistance.
The purpose of the survey is to further study and understand the epidemiology of malaria in
the refugee camp population using cutting-edge technology (RT-PCR) .
| Status | Completed |
| Enrollment | 908 |
| Est. completion date | December 2013 |
| Est. primary completion date | December 2013 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 12 Months and older |
| Eligibility |
Inclusion Criteria: - Head of household and all family members - Overnight guests - Age > 12 months - Willing to participate in the study and sign informed consent Exclusion Criteria: - All children < 1 year - Anyone reported history of abnormal blood coagulation - Anyone who does not consent to participate in the survey |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Country | Name | City | State |
|---|---|---|---|
| Thailand | Refugee Camps | Mae Sot | Tak |
| Lead Sponsor | Collaborator |
|---|---|
| University of Oxford |
Thailand,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Malaria prevalence | Comparison of malaria prevalence by conventional microscopy and RT-PCR to determine the malaria epidemiology in the population | 1 day | No |
| Secondary | Determine the percentage of households with at least one long lasting insecticide treated nets (LLIN) or insecticide treated nets (ITNs | • percentage of households with at least one long lasting insecticide treated nets (LLIN) or insecticide treated nets (ITNs) per 2 persons | 1 day | No |
| Secondary | Determine the percentage of refugees sleeping under an ITN/LLIN previous night | Percentage of refugees sleeping under an ITN/LLIN previous night | 1 day | No |
| Secondary | Determine the percentage of refugees who can recall at least 1 key messages on malaria control and containment/elimination | The percentage of refugees who can recall at least 1 key messages on malaria control and containment/elimination | 1 day | No |
| Secondary | Determine percentage of refugees who stay overnight outside the camp | The percentage of refugees who stay overnight outside the camp | 1 day | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Completed |
NCT02536222 -
Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts
|
Phase 4 |